

MEDIA RELEASE: Sydney, Australia. Tuesday 14 May, 2013.

NEW PHEBRA PLANT RECEIVES TGA MANUFACTURING LICENCE

The Australian pharmaceutical firm, Phebra, has welcomed the granting of its licence for its new Sydney sterile manufacturing plant by the Australian Therapeutic Goods Administration (TGA).

Phebra's Chief Executive Officer, Dr Mal Eutick, said the licence was granted on Monday 13 May following stringent TGA assessments of the new plant at Lane Cove West, including an ongoing series of product validations, confirming Phebra's compliance to good manufacturing practice guidelines (GMP).

The TGA testing regime is one of the most stringent testing regimes for pharmaceutical manufacturers anywhere in the world and is valued in many countries

"This is a great day for Phebra, our staff and all of our contractors who have worked together on the project over the past three years," Dr Eutick, said.

"Our General Manager Andre Vlok and Manufacturing Manager Stephen Kenny, in particular, have worked closely with the TGA to ensure that Phebra has successfully completed the regulatory requirements for our manufacturing licence.

"The plant is testament to Phebra's investment in the future of the local manufacturing industry."

Upon opening the plant in March, the Federal Minister for Industry and Innovation, Greg Combet, said that the Australian pharmaceutical industry "employs 40,000 Australians, generates export earnings of around \$4 billion a year and invests more than \$1 billion a year in research and development."

"In line with the Minister's comments, the new plant will allow Phebra to significantly boost our research and production capacity, for the Australian and overseas markets," Dr Eutick explained.

"We will be manufacturing our ever-growing range of critical medicines, including emergency injectables, antidotes and other small volume injections.

"We will also be expanding our capability to conduct all-important development programs now and into the future, providing skills development and employment for Australian scientists and medical researchers."



ABOUT PHEBRA

Phebra is an Australian specialty pharmaceutical company that develops, manufactures and markets critical medicines in Australia, New Zealand, Asia, Canada and parts of Europe.

The company's critical medicines cover a range of pharmaceuticals in important disease areas such as cystic fibrosis, antidotes, diagnostics, oncology and pain.

At Phebra, we create critical medicines that save and improve lives.

Media contact:

Richard Lenarduzzi at The Premier Communications Group

+61 2 92303075

info@premiercomms.com.au